Rainer Schulz

List of Publications by Year in Descending Order

249 papers	17,993 citations	68 h-index	127 g-index
279 ext. papers	20,522 ext. citations	8.1 avg, IF	6.68 L-index

#	Paper	IF	Citations
249	Redox regulatory changes of circadian rhythm by the environmental risk factors traffic noise and air pollution.. *Antioxidants and Redox Signaling*, **2022**,	8.4	3
248	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.. *Cardiovascular Research*, **2022**,	9.9	3
247	Somatostatin and Its Receptors in Myocardial Ischemia/Reperfusion Injury and Cardioprotection. *Frontiers in Pharmacology*, **2021**, 12, 663655	5.6	0
246	Cardiomyocytes-specific deletion of monoamine oxidase B reduces irreversible myocardial ischemia/reperfusion injury. *Free Radical Biology and Medicine*, **2021**, 165, 14-23	7.8	7
245	Influence of cardiometabolic comorbidities on myocardial function, infarction, and cardioprotection: Role of cardiac redox signaling. *Free Radical Biology and Medicine*, **2021**, 166, 33-52	7.8	9
244	Vascular and Cardiac Oxidative Stress and Inflammation as Targets for Cardioprotection. *Current Pharmaceutical Design*, **2021**, 27, 2112-2130	3.3	7
243	AIM2-driven inflammasome activation in heart failure. *Cardiovascular Research*, **2021**, 117, 2639-2651	9.9	2
242	PI3K as Mediator of Apoptosis and Contractile Dysfunction in TGF□Stimulated Cardiomyocytes. *Biology*, **2021**, 10,	4.9	1
241	Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2021**, 117, 367-385	9.9	24
240	RyR2 regulates Cx43 hemichannel intracellular Ca2+-dependent activation in cardiomyocytes. *Cardiovascular Research*, **2021**, 117, 123-136	9.9	13
239	Purinergic Regulation of Endothelial Barrier Function. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
238	Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes. *Frontiers in Physiology*, **2021**, 12, 593862	4.6	4
237	Thiol-based redox-active proteins as cardioprotective therapeutic agents in cardiovascular diseases. *Basic Research in Cardiology*, **2021**, 116, 44	11.8	6
236	IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. *Basic Research in Cardiology*, **2021**, 116, 52	11.8	11
235	Molecular Network Approach Reveals as a Central Target of Cardiac ProtectomiRs. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
234	Matrix Metalloproteinases Repress Hypertrophic Growth in Cardiac Myocytes. *Cardiovascular Drugs and Therapy*, **2021**, 35, 353-365	3.9	2
233	Importance of Cx43 for Right Ventricular Function. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5

232	Lack of Contribution of p66shc to Pressure Overload-Induced Right Heart Hypertrophy. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
231	Genetic Deletion of p66shc and/or Cyclophilin D Results in Decreased Pulmonary Vascular Tone. *Cardiovascular Research*, **2020**,	9.9	2
230	Autocrine effects of PCSK9 on cardiomyocytes. *Basic Research in Cardiology*, **2020**, 115, 65	11.8	4
229	CTRP9 Mediates Protective Effects in Cardiomyocytes via AMPK- and Adiponectin Receptor-Mediated Induction of Anti-Oxidant Response. *Cells*, **2020**, 9,	7.9	13
228	Induction of Proteasome Subunit Low Molecular Weight Protein (LMP)-2 Is Required to Induce Active Remodeling in Adult Rat Ventricular Cardiomyocytes. *Medical Sciences (Basel, Switzerland)*, **2020**, 8,	3.3	1
227	Oxidative stress and inflammation contribute to traffic noise-induced vascular and cerebral dysfunction via uncoupling of nitric oxide synthases. *Redox Biology*, **2020**, 34, 101506	11.3	27
226	Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function. *Cardiovascular Research*, **2020**, 116, 1835-1849	9.9	15
225	The role of mitochondrial reactive oxygen species, NO and H S in ischaemia/reperfusion injury and cardioprotection. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 6510-6522	5.6	39
224	Swiprosin-1/EFhD-2 Expression in Cardiac Remodeling and Post-Infarct Repair: Effect of Ischemic Conditioning. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
223	Mitochondrial ion channels as targets for cardioprotection. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 7102-7114	5.6	27
222	Hidden Cardiotoxicity of Rofecoxib Can be Revealed in Experimental Models of Ischemia/Reperfusion. *Cells*, **2020**, 9,	7.9	8
221	Cardioprotection in right heart failure. *British Journal of Pharmacology*, **2020**, 177, 5413-5431	8.6	4
220	Influence of mental stress and environmental toxins on circadian clocks: Implications for redox regulation of the heart and cardioprotection. *British Journal of Pharmacology*, **2020**, 177, 5393-5412	8.6	23
219	Ageing, sex, and cardioprotection. *British Journal of Pharmacology*, **2020**, 177, 5270-5286	8.6	18
218	Differential effects of right and left heart failure on skeletal muscle in rats. *Journal of Cachexia, Sarcopenia and Muscle*, **2020**, 11, 1830-1849	10.3	2
217	Structural, Pro-Inflammatory and Calcium Handling Remodeling Underlies Spontaneous Onset of Paroxysmal Atrial Fibrillation in JDP2-Overexpressing Mice. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
216	Effects of air pollution particles (ultrafine and fine particulate matter) on mitochondrial function and oxidative stress - Implications for cardiovascular and neurodegenerative diseases. *Archives of Biochemistry and Biophysics*, **2020**, 696, 108662	4.1	22
215	Cardiac miRNA Expression and their mRNA Targets in a Rat Model of Prediabetes. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5

214	Transcriptional Alterations by Ischaemic Postconditioning in a Pig Infarction Model: Impact on Microvascular Protection. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	8
213	P66shc and its role in ischemic cardiovascular diseases. *Basic Research in Cardiology*, **2019**, 114, 29	11.8	23
212	Investigating and re-evaluating the role of glycogen synthase kinase 3 beta kinase as a molecular target for cardioprotection by using novel pharmacological inhibitors. *Cardiovascular Research*, **2019**, 115, 1228-1243	9.9	17
211	Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. *Cardiovascular Research*, **2019**, 115, 1117-1130	9.9	77
210	Protection against pressure overload-induced right heart failure by uncoupling protein 2 silencing. *Cardiovascular Research*, **2019**, 115, 1217-1227	9.9	12
209	Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. *European Heart Journal*, **2019**, 40, 1771-1777	9.5	49
208	Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. *European Heart Journal*, **2019**, 40, 2432-2440	9.5	28
207	Professor David Garcia-Dorado 1953-2019. *European Heart Journal*, **2019**, 40, 3670-3671	9.5	
206	Professor David Garcia-Dorado 1953–2019 Obituary. *Cardiovascular Research*, **2019**, 115, 1933-1934	9.9	
205	The coronary circulation in acute myocardial ischaemia/reperfusion injury: a target for cardioprotection. *Cardiovascular Research*, **2019**, 115, 1143-1155	9.9	77
204	Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. *Journal of the American College of Cardiology*, **2019**, 73, 89-99	15.1	292
203	Connexins in cardiac ischemia. *Current Opinion in Physiology*, **2018**, 2, 123-128	2.6	5
202	Nagarse treatment of cardiac subsarcolemmal and interfibrillar mitochondria leads to artefacts in mitochondrial protein quantification. *Journal of Pharmacological and Toxicological Methods*, **2018**, 91, 50-58	1.7	9
201	Phosphoinositide 3-Kinase Gamma Inhibition Protects From Anthracycline Cardiotoxicity and Reduces Tumor Growth. *Circulation*, **2018**, 138, 696-711	16.7	83
200	Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovascular Research*, **2018**, 114, 19-34	9.9	198
199	Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. *Vascular Pharmacology*, **2018**,	5.9	8
198	Mitochondria "THE" target of myocardial conditioning. *American Journal of Physiology - Heart and Circulatory Physiology*, **2018**, 315, H1215-H1231	5.2	45
197	Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. *Basic Research in Cardiology*, **2018**, 113, 39	11.8	224

196	Review on Chamber-Specific Differences in Right and Left Heart Reactive Oxygen Species Handling. *Frontiers in Physiology*, **2018**, 9, 1799	4.6	11
195	MicroRNA expression profile of human advanced coronary atherosclerotic plaques. *Scientific Reports*, **2018**, 8, 7823	4.9	38
194	JDP2 overexpression provokes cardiac dysfunction in mice. *Scientific Reports*, **2018**, 8, 7647	4.9	10
193	Selegiline reduces adiposity induced by high-fat, high-sucrose diet in male rats. *British Journal of Pharmacology*, **2018**, 175, 3713-3726	8.6	13
192	New aspects of p66Shc in ischaemia reperfusion injury and other cardiovascular diseases. *British Journal of Pharmacology*, **2017**, 174, 1690-1703	8.6	41
191	Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature. *British Journal of Pharmacology*, **2017**, 174, 497-511	8.6	11
190	Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. *British Journal of Pharmacology*, **2017**, 174, 1555-1569	8.6	49
189	PCSK9 targets important for lipid metabolism. *Clinical Research in Cardiology Supplements*, **2017**, 12, 2-11	3.1	28
188	Mitochondria and ageing: role in heart, skeletal muscle and adipose tissue. *Journal of Cachexia, Sarcopenia and Muscle*, **2017**, 8, 349-369	10.3	160
187	Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease. *Basic Research in Cardiology*, **2017**, 112, 32	11.8	45
186	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2017**, 113, 725-736	9.9	85
185	European contribution to the study of ROS: A summary of the findings and prospects for the future from the COST action BM1203 (EU-ROS). *Redox Biology*, **2017**, 13, 94-162	11.3	185
184	Connexin 43 and Mitochondria in Cardiovascular Health and Disease. *Advances in Experimental Medicine and Biology*, **2017**, 982, 227-246	3.6	49
183	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2017**, 113, 564-585	9.9	206
182	Mitochondrial Cx43 hemichannels contribute to mitochondrial calcium entry and cell death in the heart. *Basic Research in Cardiology*, **2017**, 112, 27	11.8	76
181	The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43. *British Journal of Pharmacology*, **2017**, 174, 2060-2073	8.6	23
180	AP39, a mitochondria-targeting hydrogen sulfide (H S) donor, protects against myocardial reperfusion injury independently of salvage kinase signalling. *British Journal of Pharmacology*, **2017**, 174, 287-301	8.6	52
179	Pharmacological Intervention to Modulate HDL: What Do We Target?. *Frontiers in Pharmacology*, **2017**, 8, 989	5.6	25

178	Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way. *Basic Research in Cardiology*, **2017**, 112, 63	11.8	37
177	Connexins in Cardiovascular and Neurovascular Health and Disease: Pharmacological Implications. *Pharmacological Reviews*, **2017**, 69, 396-478	22.5	134
176	Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. *Cardiovascular Research*, **2017**, 113, 1418-1419	9.9	9
175	In vivo MRI and ex vivo histological assessment of the cardioprotection induced by ischemic preconditioning, postconditioning and remote conditioning in a closed-chest porcine model of reperfused acute myocardial infarction: importance of microvasculature. *Journal of Translational Medicine*, **2017**, 15, 67	8.5	24
174	Effect of nitric oxide deficiency on the pulmonary PTHrP system. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 96-106	5.6	3
173	Adverse Effects on β-Adrenergic Receptor Coupling: Ischemic Postconditioning Failed to Preserve Long-Term Cardiac Function. *Journal of the American Heart Association*, **2017**, 6,	6	7
172	Effect of ticagrelor on endothelial calcium signalling and barrier function. *Thrombosis and Haemostasis*, **2017**, 117, 371-381	7	10
171	Identification of microRNAs as potential cellular monocytic biomarkers in the early phase of myocardial infarction: a pilot study. *Scientific Reports*, **2017**, 7, 15974	4.9	12
170	Lack of Contribution of p66shc and Its Mitochondrial Translocation to Ischemia-Reperfusion Injury and Cardioprotection by Ischemic Preconditioning. *Frontiers in Physiology*, **2017**, 8, 733	4.6	16
169	Endothelial Mesenchymal Transition in Hypoxic Microvascular Endothelial Cells and Paracrine Induction of Cardiomyocyte Apoptosis Are Mediated via TGFβ/SMAD Signaling. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	22
168	From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research". *Basic Research in Cardiology*, **2016**, 111, 69	11.8	36
167	Oxidative Stress and Nitrosative Stress **2016**, 267-278		0
166	A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial. *American Heart Journal*, **2016**, 179, 69-76	4.9	12
165	Effects of P2Y12 receptor antagonists beyond platelet inhibition--comparison of ticagrelor with thienopyridines. *British Journal of Pharmacology*, **2016**, 173, 1163-78	8.6	66
164	Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. *European Heart Journal*, **2016**, 37, 1789-98	9.5	163
163	Diastolic dysfunction in prediabetic male rats: Role of mitochondrial oxidative stress. *American Journal of Physiology - Heart and Circulatory Physiology*, **2016**, 311, H927-H943	5.2	54
162	Connexin 43 is an emerging therapeutic target in ischemia/reperfusion injury, cardioprotection and neuroprotection. *Pharmacology & Therapeutics*, **2015**, 153, 90-106	13.9	146
161	Platelet inhibitors influence cardioprotection: importance in preclinical study design: reply. *Cardiovascular Research*, **2015**, 106, 8	9.9	1

160	Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9). *Basic Research in Cardiology*, **2015**, 110, 4	11.8	68
159	Ischemia and reperfusion related myocardial inflammation: A network of cells and mediators targeting the cardiomyocyte. *IUBMB Life*, **2015**, 67, 110-9	4.7	21
158	Specific Mechanisms Underlying Right Heart Failure: The Missing Upregulation of Superoxide Dismutase-2 and Its Decisive Role in Antioxidative Defense. *Antioxidants and Redox Signaling*, **2015**, 23, 1220-32	8.4	21
157	Compound C inhibits in vitro angiogenesis and ameliorates thrombin-induced endothelial barrier failure. *European Journal of Pharmacology*, **2015**, 768, 165-72	5.3	6
156	The role of gasotransmitters NO, H2S and CO in myocardial ischaemia/reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning. *British Journal of Pharmacology*, **2015**, 172, 1587-606	8.6	142
155	Mechanism and consequences of the shift in cardiac arginine metabolism following ischaemia and reperfusion in rats. *Thrombosis and Haemostasis*, **2015**, 113, 482-93	7	17
154	Interaction between connexin 43 and nitric oxide synthase in mice heart mitochondria. *Journal of Cellular and Molecular Medicine*, **2015**, 19, 815-25	5.6	27
153	NOX4 in Mitochondria: Yeast Two-Hybrid-Based Interaction with Complex I Without Relevance for Basal Reactive Oxygen Species?. *Antioxidants and Redox Signaling*, **2015**, 23, 1106-12	8.4	35
152	Novel therapeutic strategies for cardioprotection. *Pharmacology & Therapeutics*, **2014**, 144, 60-70	13.9	57
151	Nitrite in organ protection. *British Journal of Pharmacology*, **2014**, 171, 1-11	8.6	44
150	Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. *Pharmacological Reviews*, **2014**, 66, 1142-74	22.5	424
149	S-nitrosation of mitochondrial connexin 43 regulates mitochondrial function. *Basic Research in Cardiology*, **2014**, 109, 433	11.8	51
148	Association of bilirubin with coronary artery calcification and cardiovascular events in the general population without known liver disease: the Heinz Nixdorf Recall study. *Clinical Research in Cardiology*, **2014**, 103, 647-53	6.1	31
147	Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. *Journal of the American College of Cardiology*, **2014**, 63, 2503-2509	15.1	221
146	cAMP controls the restoration of endothelial barrier function after thrombin-induced hyperpermeability via Rac1 activation. *Physiological Reports*, **2014**, 2, e12175	2.6	34
145	ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. *Cardiovascular Research*, **2014**, 104, 399-411	9.9	108
144	Impact of caloric restriction on myocardial ischaemia/reperfusion injury and new therapeutic options to mimic its effects. *British Journal of Pharmacology*, **2014**, 171, 2964-92	8.6	20
143	The cellular prion protein counteracts cardiac oxidative stress. *Cardiovascular Research*, **2014**, 104, 93-102	9.9	21

142	Nucleoside triphosphates inhibit ADP, collagen, and epinephrine-induced platelet aggregation: role of P2Y and P2Y receptors. *Thrombosis Research*, **2013**, 132, 548-57	8.2	10
141	Mechanisms involved in postconditioning protection of cardiomyocytes against acute reperfusion injury. *Journal of Molecular and Cellular Cardiology*, **2013**, 58, 209-16	5.8	30
140	Mesenteric ischemia-reperfusion injury: clearly improved hemodynamics but only minor protection of the rat small intestine by (sub)therapeutic heparin sodium and enoxaparin doses. *Journal of Surgical Research*, **2013**, 179, e57-69	2.5	8
139	Hypoxia-reoxygenation-induced endothelial barrier failure: role of RhoA, Rac1 and myosin light chain kinase. *Journal of Physiology*, **2013**, 591, 461-73	3.9	37
138	Selective inhibition of Cx43 hemichannels by Gap19 and its impact on myocardial ischemia/reperfusion injury. *Basic Research in Cardiology*, **2013**, 108, 309	11.8	172
137	Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovascular Research*, **2013**, 98, 7-27	9.9	172
136	Inhibition of AP-1 signaling by JDP2 overexpression protects cardiomyocytes against hypertrophy and apoptosis induction. *Cardiovascular Research*, **2013**, 99, 121-8	9.9	29
135	Monoamine oxidases are mediators of endothelial dysfunction in the mouse aorta. *Hypertension*, **2013**, 62, 140-6	8.5	63
134	The STAT3 inhibitor stattic impairs cardiomyocyte mitochondrial function through increased reactive oxygen species formation. *Current Pharmaceutical Design*, **2013**, 19, 6890-5	3.3	61
133	Connexin 43 impacts on mitochondrial potassium uptake. *Frontiers in Pharmacology*, **2013**, 4, 73	5.6	43
132	Old and new biomarkers of oxidative stress in heart failure. *Drug Discovery Today: Therapeutic Strategies*, **2012**, 9, e189-e198		4
131	Glycine, a simple physiological compound protecting by yet puzzling mechanism(s) against ischaemia-reperfusion injury: current knowledge. *British Journal of Pharmacology*, **2012**, 165, 2059-72	8.6	30
130	The coronary circulation in cardioprotection: more than just one confounder. *Cardiovascular Research*, **2012**, 94, 237-45	9.9	58
129	Mitochondrial connexin 43 impacts on respiratory complex I activity and mitochondrial oxygen consumption. *Journal of Cellular and Molecular Medicine*, **2012**, 16, 1649-55	5.6	85
128	Cardiomyocyte-specific deletion of survivin causes global cardiac conduction defects. *Basic Research in Cardiology*, **2012**, 107, 299	11.8	9
127	Pleiotropic effects of dronedarone on ischemia/reperfusion injury in heart and brain. *Cardiovascular Drugs and Therapy*, **2012**, 26, 257-63	3.9	3
126	Glycogen synthase kinase 3 transfers cytoprotective signaling through connexin 43 onto mitochondrial ATP-sensitive K+ channels. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, E242-51	11.5	22
125	Mitochondria in postconditioning. *Antioxidants and Redox Signaling*, **2011**, 14, 863-80	8.4	50

124	Cholesterol diet leads to attenuation of ischemic preconditioning-induced cardiac protection: the role of connexin 43. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H1907-13	5.2	47
123	The in-situ pig heart with regional ischemia/reperfusion - ready for translation. *Journal of Molecular and Cellular Cardiology*, **2011**, 50, 951-63	5.8	75
122	Cardioprotection by ivabradine through heart rate reduction and beyond. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2011**, 16, 281-4	2.6	13
121	Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. *British Journal of Pharmacology*, **2011**, 163, 469-83	8.6	66
120	Nuclear-encoded mitochondrial proteins and their role in cardioprotection. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2011**, 1813, 1286-94	4.9	46
119	Preface to mitochondria and cardioprotection. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2011**, 1813, 1261-2	4.9	2
118	TNF in myocardial ischemia/reperfusion, remodeling and heart failure. *Heart Failure Reviews*, **2011**, 16, 49-69	5	175
117	Reduction of cerebral infarct size by dronedarone. *Cardiovascular Drugs and Therapy*, **2011**, 25, 523-9	3.9	11
116	Vasoconstrictor potential of coronary aspirate from patients undergoing stenting of saphenous vein aortocoronary bypass grafts and its pharmacological attenuation. *Circulation Research*, **2011**, 108, 344-52	15.7	75
115	Connexin 43 acts as a cytoprotective mediator of signal transduction by stimulating mitochondrial KATP channels in mouse cardiomyocytes. *Journal of Clinical Investigation*, **2010**, 120, 1441-53	15.9	64
114	Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H446-53	5.2	43
113	Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. *Cardiovascular Research*, **2010**, 85, 110-7	9.9	56
112	Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovascular Research*, **2010**, 87, 406-23	9.9	410
111	Inhibition of permeability transition pore opening by mitochondrial STAT3 and its role in myocardial ischemia/reperfusion. *Basic Research in Cardiology*, **2010**, 105, 771-85	11.8	291
110	Cyclosporine A at reperfusion reduces infarct size in pigs. *Cardiovascular Drugs and Therapy*, **2010**, 24, 85-7	3.9	80
109	TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. *Pharmacology & Therapeutics*, **2010**, 127, 295-314	13.9	303
108	Loss of cardioprotection with ageing. *Cardiovascular Research*, **2009**, 83, 247-61	9.9	250
107	Connexin43 in cardiomyocyte mitochondria contributes to mitochondrial potassium uptake. *Cardiovascular Research*, **2009**, 83, 747-56	9.9	107

106	Coronary microembolization: from bedside to bench and back to bedside. *Circulation*, **2009**, 120, 1822-36	16.7	310
105	Presence of connexin 43 in subsarcolemmal, but not in interfibrillar cardiomyocyte mitochondria. *Basic Research in Cardiology*, **2009**, 104, 141-7	11.8	133
104	Ischemic postconditioning: experimental models and protocol algorithms. *Basic Research in Cardiology*, **2009**, 104, 469-83	11.8	172
103	Ischemic postconditioning in pigs: no causal role for RISK activation. *Circulation Research*, **2009**, 104, 15-8	15.7	220
102	New insights into the S-nitrosothiol-ascorbate reaction. The formation of nitroxyl. *Organic and Biomolecular Chemistry*, **2009**, 7, 1954-62	3.9	38
101	The myocardial JAK/STAT pathway: from protection to failure **2008**, 120, 172-85		259
100	TNFalpha in myocardial ischemia/reperfusion: damage vs. protection. *Journal of Molecular and Cellular Cardiology*, **2008**, 45, 712-4	5.8	15
99	Forest structure and woody plant species composition along a fire chronosequence in mixed pine–oak forest in the Sierra Madre Oriental, Northeast Mexico. *Forest Ecology and Management*, **2008**, 256, 161-167	3.9	45
98	Extracellular adenosine attenuates left ventricular hypertrophy through its impact on the protein kinase and phosphatase interaction. *Hypertension*, **2008**, 51, 1474-5	8.5	2
97	Improvement of regional myocardial blood flow and function and reduction of infarct size with ivabradine: protection beyond heart rate reduction. *European Heart Journal*, **2008**, 29, 2265-75	9.5	112
96	Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. *Circulation Research*, **2008**, 102, 131-5	15.7	225
95	No impact of protein phosphatases on connexin 43 phosphorylation in ischemic preconditioning. *American Journal of Physiology - Heart and Circulatory Physiology*, **2008**, 295, H2106-12	5.2	24
94	Inducible nitric oxide synthase expression and cardiomyocyte dysfunction during sustained moderate ischemia in pigs. *Circulation Research*, **2008**, 103, 1120-7	15.7	49
93	Cardioprotection: nitric oxide, protein kinases, and mitochondria. *Circulation*, **2008**, 118, 1915-9	16.7	359
92	Pathophysiology of myocardial infarction: protection by ischemic pre- and postconditioning. *Herz*, **2008**, 33, 88-100	2.6	89
91	Reduced calcium responsiveness characterizes contractile dysfunction following coronary microembolization. *Basic Research in Cardiology*, **2008**, 103, 552-9	11.8	17
90	Regulation and role of the presynaptic and myocardial Na+/H+ exchanger NHE1: effects on the sympathetic nervous system in heart failure. *Cardiovascular Drug Reviews*, **2007**, 25, 123-31		27
89	Connexin 43 in ischemic pre- and postconditioning. *Heart Failure Reviews*, **2007**, 12, 261-6	5	76

88	Loss of ischemic preconditioning3 cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43. *American Journal of Physiology - Heart and Circulatory Physiology*, **2007**, 292, H1764-9	5.2	143
87	Microdialysis-based analysis of interstitial NO in situ: NO synthase-independent NO formation during myocardial ischemia. *Cardiovascular Research*, **2007**, 74, 46-55	9.9	39
86	The role of heart rate and the benefits of heart rate reduction in acute myocardial ischaemia. *Country Review Ukraine*, **2007**, 9, F8-F14		9
85	Bidirectional role of tumor necrosis factor-alpha in coronary microembolization: progressive contractile dysfunction versus delayed protection against infarction. *Circulation Research*, **2007**, 100, 140-6	15.7	131
84	Mitochondrial respiration and membrane potential after low-flow ischemia are not affected by ischemic preconditioning. *Journal of Molecular and Cellular Cardiology*, **2007**, 43, 610-5	5.8	13
83	A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. *Cell*, **2007**, 128, 589-600	56.2	586
82	The impact of subarachnoid hemorrhage on regional cerebral blood flow and large-vessel diameter in the canine model of chronic vasospasm. *Journal of Stroke and Cerebrovascular Diseases*, **2007**, 16, 45-51	2.8	5
81	Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. *Pharmacological Reviews*, **2007**, 59, 418-58	22.5	567
80	Connexin 43 and ischemic preconditioning: effects of age and disease. *Experimental Gerontology*, **2006**, 41, 485-8	4.5	26
79	Positive effects of nitric oxide on left ventricular function in humans. *European Heart Journal*, **2006**, 27, 1699-705	9.5	81
78	Oxidative modification of tropomyosin and myocardial dysfunction following coronary microembolization. *European Heart Journal*, **2006**, 27, 875-81	9.5	131
77	Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS. *American Journal of Physiology - Heart and Circulatory Physiology*, **2006**, 290, H450-7	5.2	34
76	Formation of reactive oxygen species at increased contraction frequency in rat cardiomyocytes. *Cardiovascular Research*, **2006**, 71, 374-82	9.9	50
75	Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. *Circulation Research*, **2006**, 99, 93-101	15.7	195
74	High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. *Circulation* , **2006**, 114, 1403-9	16.7	324
73	ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. *Circulation Research*, **2006**, 99, 1100-8	15.7	282
72	Connexin43 and ischemic preconditioning. *Advances in Cardiology*, **2006**, 42, 213-227		32
71	Red blood cells express a functional endothelial nitric oxide synthase. *Blood*, **2006**, 107, 2943-51	2.2	414

70	Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. *Neuroscience Letters*, **2006**, 406, 92-6	3.3	23
69	Prevention of the ischemia-induced decrease in mitochondrial Tom20 content by ischemic preconditioning. *Journal of Molecular and Cellular Cardiology*, **2006**, 41, 426-30	5.8	27
68	Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: initiation of inflammation. *Journal of Hypertension*, **2006**, 24, S123-9	1.9	16
67	Inhibition of Na+/H+-exchanger with sabiporide attenuates the downregulation and uncoupling of the myocardial beta-adrenoceptor system in failing rabbit hearts. *British Journal of Pharmacology*, **2006**, 148, 137-46	8.6	11
66	No loss of cardioprotection by postconditioning in connexin 43-deficient mice. *Basic Research in Cardiology*, **2006**, 101, 354-6	11.8	89
65	Transactions that did not happen and their influence on prices. *Journal of Economic Behavior and Organization*, **2005**, 56, 567-591	1.6	16
64	Preinfarction angina: no interference of coronary microembolization with acute ischemic preconditioning. *Journal of Molecular and Cellular Cardiology*, **2005**, 39, 355-61	5.8	15
63	Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. *Cardiovascular Research*, **2005**, 67, 234-44	9.9	230
62	Making profits in wartime: corporate profits, inequality, and GDP in Germany during the First World War1. *Economic History Review*, **2005**, 58, 34-56	1.7	12
61	Regional differences of myocardial infarct development and ischemic preconditioning. *Basic Research in Cardiology*, **2005**, 100, 48-56	11.8	12
60	Myocardial hibernation: a delicate balance. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H984-99	5.2	149
59	Impaired resting perfusion in viable myocardium distal to chronic coronary stenosis in rats. *American Journal of Physiology - Heart and Circulatory Physiology*, **2005**, 288, H2588-93	5.2	14
58	Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotection in connexin 43 deficient mice. *Circulation Research*, **2005**, 97, 583-6	15.7	201
57	Overview of contemporary reperfusion strategies in acute ST-elevation myocardial infarction. *Expert Review of Cardiovascular Therapy*, **2005**, 3, 667-80	2.5	
56	Nitric oxide in myocardial ischemia/reperfusion injury. *Cardiovascular Research*, **2004**, 61, 402-13	9.9	333
55	Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. *Circulation Research*, **2004**, 95, 187-95	15.7	316
54	HFA1 encoding an organelle-specific acetyl-CoA carboxylase controls mitochondrial fatty acid synthesis in Saccharomyces cerevisiae. *Journal of Biological Chemistry*, **2004**, 279, 21779-86	5.4	63
53	Glucocorticoid treatment prevents progressive myocardial dysfunction resulting from experimental coronary microembolization. *Circulation*, **2004**, 109, 2337-42	16.7	72

52	Connexin 43 and ischemic preconditioning. *Cardiovascular Research*, **2004**, 62, 335-44	9.9	68
51	Chronic treatment with fluvastatin improves smooth muscle dilatory function in genetically determined hyperlipoproteinemia. *Journal of Cardiovascular Pharmacology*, **2004**, 43, 183-90	3.1	4
50	Inhibition of the Na+/H+ exchanger attenuates the deterioration of ventricular function during pacing-induced heart failure in rabbits. *Cardiovascular Research*, **2004**, 63, 273-82	9.9	54
49	Coronary microembolization does not induce acute preconditioning against infarction in pigs-the role of adenosine. *Cardiovascular Research*, **2004**, 63, 313-22	9.9	22
48	A State Space Model for Berlin House Prices: Estimation and Economic Interpretation. *Journal of Real Estate Finance and Economics*, **2004**, 28, 37-57	1.1	19
47	TNFalpha in ischemia/reperfusion injury and heart failure. *Basic Research in Cardiology*, **2004**, 99, 8-11	11.8	59
46	Coronary microembolization. *Journal of Molecular and Cellular Cardiology*, **2004**, 37, 23-31	5.8	73
45	Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. *Free Radical Biology and Medicine*, **2003**, 35, 790-6	7.8	468
44	Activation of ATP-dependent potassium channels is a trigger but not a mediator of ischaemic preconditioning in pigs. *British Journal of Pharmacology*, **2003**, 139, 65-72	8.6	15
43	Plasma nitrosothiols contribute to the systemic vasodilator effects of intravenously applied NO: experimental and clinical Study on the fate of NO in human blood. *Circulation Research*, **2002**, 91, 470-7	15.7	153
42	Hibernating myocardium: new answers, still more questions!. *Circulation Research*, **2002**, 91, 863-5	15.7	13
41	Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction. *Circulation*, **2002**, 106, 2180-3	16.7	141
40	Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. *Circulation Research*, **2002**, 90, 807-13	15.7	166
39	p38 MAP kinase is a mediator of ischemic preconditioning in pigs. *Cardiovascular Research*, **2002**, 55, 690-700	9.9	57
38	Involvement of endogenous prostaglandins in ischemic preconditioning in pigs. *Cardiovascular Research*, **2002**, 55, 626-32	9.9	23
37	Coronary microembolization: the role of TNF-alpha in contractile dysfunction. *Journal of Molecular and Cellular Cardiology*, **2002**, 34, 51-62	5.8	161
36	Perfusion-contraction match and mismatch. *Basic Research in Cardiology*, **2001**, 96, 1-10	11.8	28
35	Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. *American Journal of Hematology*, **2001**, 66, 245-51	7.1	67

34	Balance and imbalance of regional myocardial contractile function and blood flow. *Clinical Research in Cardiology*, **2001**, 90, 964-9		6
33	Coronary microembolization. *Progress in Cardiovascular Diseases*, **2001**, 44, 217-30	8.5	33
32	The biology of myocardial hibernation. *Trends in Cardiovascular Medicine*, **2000**, 10, 108-14	6.9	19
31	X-ray densitometry for the measurement of regional myocardial perfusion. *Basic Research in Cardiology*, **2000**, 95, 261-70	11.8	9
30	No involvement of endogenous nitric oxide in classical ischemic preconditioning in swine. *Journal of Molecular and Cellular Cardiology*, **2000**, 32, 725-33	5.8	59
29	The stress-responsive MAP kinase p38 is activated by low-flow ischemia in the in situ porcine heart. *Journal of Molecular and Cellular Cardiology*, **2000**, 32, 1787-94	5.8	21
28	Effectiveness of low dose captopril versus propranolol therapy in infants with severe congestive failure due to left-to-right shunts. *International Journal of Cardiology*, **2000**, 76, 227-33	3.2	19
27	The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects. *British Journal of Clinical Pharmacology*, **1999**, 47, 701-6	3.8	22
26	Effects of verapamil and mibefradil on regional blood flow and function in normal and ischemic myocardium. *Cardiovascular Drugs and Therapy*, **1999**, 13, 275-6	3.9	1
25	Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. *Cancer Chemotherapy and Pharmacology*, **1999**, 43, 309-15	3.5	57
24	Quantification of cardioprotective gene expression in porcine short-term hibernating myocardium. *Journal of Molecular and Cellular Cardiology*, **1999**, 31, 147-58	5.8	9
23	Features of short-term myocardial hibernation **1998**, 186, 185-193		8
22	Beta-blocker therapy of severe congestive heart failure in infants with left to right shunts. *American Journal of Cardiology*, **1998**, 81, 1366-8	3	46
21	Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. *Journal of the American College of Cardiology*, **1998**, 32, 1787-96	15.1	158
20	Prevention of ischemic preconditioning only by combined inhibition of protein kinase C and protein tyrosine kinase in pigs. *Journal of Molecular and Cellular Cardiology*, **1998**, 30, 197-209	5.8	129
19	Impact of resting and ischemic blood flow on infarct probability in ischemic preconditioning--a new approach to infarct size-blood flow data by logistic regression. *Journal of Molecular and Cellular Cardiology*, **1998**, 30, 2719-28	5.8	11
18	Positron emission tomography analysis of [1-(11)C] acetate kinetics in short-term hibernating myocardium. *Circulation*, **1998**, 97, 1009-16	16.7	22
17	Inorganic phosphate content and free energy change of ATP hydrolysis in regional short-term hibernating myocardium. *Cardiovascular Research*, **1998**, 39, 318-26	9.9	39

16	"Myocardial stunning" remaining questions. *Cardiovascular Research*, **1998**, 38, 549-58	9.9	28
15	Expression of calcium regulatory proteins in short-term hibernation and stunning in the in situ porcine heart. *Cardiovascular Research*, **1998**, 37, 606-17	9.9	39
14	Endogenous protective mechanisms in myocardial ischemia: hibernation and ischemic preconditioning. *American Journal of Cardiology*, **1997**, 80, 26A-33A	3	11
13	Little Evidence for Lethal Reperfusion Injury to Cardiomyocytes. *Journal of Thrombosis and Thrombolysis*, **1997**, 4, 111-112	5.1	3
12	Hibernating myocardium: a review. *Journal of Molecular and Cellular Cardiology*, **1996**, 28, 2359-72	5.8	47
11	Calcium responsiveness in regional myocardial short-term hibernation and stunning in the in situ porcine heart. Inotropic responses to postextrasystolic potentiation and intracoronary calcium. *Circulation*, **1996**, 93, 1556-66	16.7	67
10	No prevention of ischemic preconditioning by the protein kinase C inhibitor staurosporine in swine. *Circulation Research*, **1996**, 79, 407-14	15.7	62
9	Involvement of endogenous adenosine in ischaemic preconditioning in swine. *Pflugers Archiv European Journal of Physiology*, **1995**, 430, 273-82	4.6	88
8	Intraischemic preconditioning. Increased tolerance to sustained low-flow ischemia by a brief episode of no-flow ischemia without intermittent reperfusion. *Circulation Research*, **1995**, 76, 942-50	15.7	41
7	CORDAT II: a new program for data acquisition and on-line calculation of hemodynamic and regional myocardial dimension parameters. *Computers in Biology and Medicine*, **1993**, 23, 359-67	7	26
6	Inactivation of recombinant plasmid DNA from a human erythropoietin-producing mouse cell line grown on a large scale. *Applied Microbiology and Biotechnology*, **1991**, 35, 622-30	5.7	4
5	Pressure-flow characteristics in the right and left ventricular perfusion territories of the right coronary artery in swine. *Pflugers Archiv European Journal of Physiology*, **1991**, 419, 622-8	4.6	10
4	Interventricular redistribution of myocardial blood flow during metabolic vasodilation. *Pflugers Archiv European Journal of Physiology*, **1991**, 417, 485-92	4.6	8
3	Minimal alpha 1- and alpha 2-adrenoceptor-mediated coronary vasoconstriction in the anaesthetized swine. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1990**, 342, 422-8	3.4	33
2	Pharmacological mechanisms to attenuate sympathetically induced myocardial ischemia. *Cardiovascular Drugs and Therapy*, **1989**, 3, 43-56	3.9	5
1	Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. *Clinical Pharmacology and Therapeutics*, **1989**, 46, 528-36	6.1	60